

TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation

Roslin J. Thoppil^{1,2#}, Ravi K. Adapala^{1,2#}, Holly C. Cappelli^{1,2}, Vinay Kondeti³, Andrew C. Dudley⁴, J. Gary Meszaros^{1,2}, Sailaja Paruchuri³, and Charles K. Thodeti^{1,2*}

¹Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272; ²School of Biomedical Sciences, Kent State University, Kent, OH 44240; ³Department of Chemistry, University of Akron, Akron, OH 44325; ⁴Department of Cell and Molecular Physiology, University of North Carolina, Chapel Hill, NC 27599.

These authors contributed equally to this work.

Running Title: TRPV4 regulates tumor endothelial cell proliferation.

*Address all correspondence to: Charles K. Thodeti, Ph.D., Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272 (Tel: 330-325-6423; Fax: 330-325-5912; Email: cthodeti@neomed.edu)

Keywords: Angiogenesis, Endothelial, ERK1/2, Proliferation, Tumor Endothelial Cell, TRPV4


Supplementary Information


Supplementary Figure Legends:

Fig.S1. qPCR analysis showing reduced expression of TRPV4 mRNA in TEC compared NEC.


Fig.S2. Photomicrographs showing the efficiency of TRPV4-EGFP transfection in tumor endothelial cells.

Fig.S3. A) Representative Western blots depicting AKT phosphorylation in NEC and TEC treated or untreated with GSK (100 nM). **B)** Densitometric analysis of the Western blots for AKT phosphorylation. AKT phosphorylation was measured by normalizing phospho-AKT to total-AKT. Significance was set at $p \leq 0.05$ and compares NEC to NEC treated with GSK and NEC to TEC.





Phase contrast



EGFP

